Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,821 |
Reported balance
After 2026-08-31 transaction · row 1
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 644 · Balance 47,821 F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 644 | $9.70 | $6,246.80 |
DisclosureSEC source: 0000882796-26-000059 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,821 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $12,500. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 33,540 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0000882796-26-000037 · form4.xml · derivative · entry 2 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,540 Underlying: Common Stock · 33,540 shares Expires 2036-06-11 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:08 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 15,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-26-000037 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,177 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 631 | $8.91 | $5,622.21 |
DisclosureSEC source: 0000882796-26-000029 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,883 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 11,180 | $8.97 | $100,284.60 |
DisclosureSEC source: 0000882796-26-000023 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,252 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.96 to $8.985. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 642 | $8.75 | $5,617.50 |
DisclosureSEC source: 0000882796-26-000005 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,432 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 783 | $7.18 | $5,621.94 |
DisclosureSEC source: 0000882796-25-000023 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,790 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 20:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 676 | $8.31 | $5,617.56 |
DisclosureSEC source: 0000882796-25-000013 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,007 F1 · shares: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 27,181 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001171843-25-003916 · ownership.xml · derivative · entry 2 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,181 Underlying: Common Stock · 27,181 shares Expires 2035-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:21 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003916 · ownership.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,331 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:39 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 8,600 | $6.32 | $54,352.00 |
DisclosureSEC source: 0001127602-24-019215 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,831 F1 · shares: These shares were sold with the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 Restricted Stock Units on June 13, 2024. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.25 to $6.42. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 49,933 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001127602-24-018728 · form4.xml · derivative · entry 2 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,933 Underlying: Common Stock · 49,933 shares Expires 2034-06-12 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:30 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 6,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018728 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,431 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018771 · form4.xml · derivative · entry 2 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018771 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,611 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:46 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017160 · form4.xml · derivative · entry 2 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:46 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017160 · form4.xml · nonDerivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,866 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:15 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 53,333 | $0.00 Strike: $15.02 | $0.00 |
DisclosureSEC source: 0001127602-21-025686 · form4.xml · derivative · entry 1 McKee Amy E · CIK 0001883764 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,333 Underlying: Common Stock · 53,333 shares Expires 2031-09-20 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. F2 · derivative.exercise_date: The option vests 1/36 per month for a period of 36 months, beginning on October 20, 2021 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.